Aspirin in Reducing Events in the Elderly

Summary

ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants \[ASPREE Investigator Group, 2013; www.aspree.org; McNeil et al 2017\]. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.

Conditions

• Functional Disability
• Dementia
• Heart Disease
• Stroke
• Cancer
• Bleeding
• Depression

Interventions

DRUG

100 mg enteric-coated aspirin

100 mg enteric-coated aspirin, taken daily

DRUG

Placebo

100 mg enteric-coated placebo

Sponsors & Collaborators

• National Health and Medical Research Council, Australia

  collaborator OTHER

• Bayer

  collaborator INDUSTRY

• Monash University

  collaborator OTHER

• Berman Center for Outcomes and Clinical Research

  collaborator OTHER

• National Institute on Aging (NIA)

  collaborator NIH

• National Cancer Institute (NCI)

  collaborator NIH

• Hennepin Healthcare Research Institute

  lead OTHER

Principal Investigators

• Anne Murray, MD, MSc · Berman Center for Outcomes and Clinical Research

• John McNeil, MBBS, PHD · Monash University

Eligibility

Min Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2010-01-31

Primary Completion

2017-12-31

Completion

2024-04-30

Countries

• United States
• Australia

Study Locations